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Abstract
Objective: To compare birth and early developmental screening outcomes for infants with and 
without in utero cannabis exposures.
Study design: Observational cohort of women receiving prenatal care within a large health 
system, live birth between10/1/15–12/1/17, and at least one infant visit. Cannabis exposure was 
through routine urine toxicology screen. Preterm birth, small for gestational age (SGA) birth, birth 
defects, and early developmental screening outcomes were assessed from birth and electronic 
health record data.
Results: Of 3435 women, 283 (8.2%) had a positive urine toxicology screen. In utero cannabis 
exposure was associated with SGA birth, adjusted rate ratio (aRR) 1.69 (95% confidence interval 
[CI]: 1.22–2.34). Abnormal 12-month developmental screens occurred in 9.1% of infants with in 
utero cannabis exposure versus 3.6% of those with negative maternal screens, aRR 1.90 (95% CI: 
0.92–3.91). Additional birth outcomes were not associated with in utero cannabis exposure.
Conclusion: Exposure to cannabis during pregnancy may adversely impact fetal growth.
Introduction
Access to cannabis continues to increase across North America. As of June 2019, eleven 
states and the District of Columbia had legalized cannabis for recreational use, and an 
additional 21 states had legalized medical use of cannabis.(1) In October 2018, Canada 
became the first large developed nation to legalize cannabis for recreational use.(2) Along 
with reducing barriers to access, laws legalizing marijuana may also impact public 
perceptions regarding the risks and benefits of cannabis, including when used during 
pregnancy.(3) Pregnant women report self-medicating with cannabis to treat nausea, anxiety 
or pain.(4–6) A 2017 study in Colorado, following marijuana legalization for medical and 
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recreational use, found that a majority of cannabis dispensaries in the state recommended 
cannabis as a treatment for morning sickness.(7)
Data from national surveys suggest that cannabis exposures in pregnancy are on the rise. In a 
national sample of US adults, between 2002 and 2016, self-reported cannabis use during 
pregnancy increased from 2.9% to 5%.(8) Others have described that up to 8% of women 
18–25 years of age self-report cannabis use in pregnancy.(9) In a recent convenience sample 
of 306 women from an urban academic obstetric clinic, 35% reported use of marijuana at the 
time their pregnancy was identified, and approximately one-third of these women reported 
continued use following their pregnancy diagnosis.(5)
Although research to date on the safety of cannabis use in pregnancy has been inconsistent, 
these exposures may confer unique effects on fetal growth and development.(10, 11) 
Delta-9-tetrahydrocannabinol (THC), the active substance in cannabis, can cross the 
placenta and enter fetal circulation.(12) Prior studies of associations between THC exposure 
and birth and developmental outcomes have been limited in their ability to control for 
important confounders such as cigarette use and socioeconomic status.(13) Others have 
relied on self-report to assess marijuana use and therefore may have underestimated 
exposures.(14, 15) Few studies to date include longitudinal assessments of infant 
development following routine, practice-based screening for cannabis exposure during 
pregnancy.
Given reported trends in prenatal cannabis use, many have called for increased research on 
birth and developmental outcomes in offspring.(10, 16–18) Among women with one or more 
prenatal visits and a subsequent live birth within a large Midwestern health system, we 
aimed to evaluate whether in utero exposure to cannabis was associated with adverse birth 
outcomes, including preterm birth, small-for-gestational age (SGA) birth, low birth weight 
and major structural birth defects. In addition, among the subset of infants with continued 
care in our health system for the first year of life, we evaluated the relationship between in 
utero cannabis exposure and abnormal developmental screens at 9 and 12 months of age.
Materials and Methods
We conducted a retrospective observational cohort study, using administrative and electronic 
health record (EHR) data from women with prenatal care and a subsequent singleton live 
birth in a large integrated health system primarily in Minnesota, where cannabis is legalized 
for medical but not for recreational use.
Study population
Our study population included women receiving prenatal care at one of 15 obstetric 
practices within a single large health system administering routine urine toxicology 
screening during prenatal visits. Using automated methods, women with a prenatal visit with 
urine toxicology screening during 7/1/15–3/31/17 were identified from the EHR. We also 
required that there was a singleton live birth occurring from 10/1/15–12/1/17 and that infants 
received primary care within the same health system for their first six months of life. Infants 
with primary care visits were identified through Current Procedural Terminology (CPT) 
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codes (99381, 99391, 99382, 99392) or International Classification of Diseases, Tenth 
revision (ICD-10-CM) codes (Z00.110, .111, .121, .129). Infants and mothers were linked 
through EHR and administrative data. Mothers with multiple gestation pregnancies or non-
live birth outcomes were excluded, as were pregnancies that could not be linked to an infant 
record.
Exposure
Since March 2015, obstetric clinics providing prenatal care within our health system have 
implemented routine urine toxicology screening for THC and other substances for all 
pregnant women (amphetamines, barbiturates, benzodiazepines, cocaine, methadone, 
opiates, oxycodone, phenylcyclidine) at the first prenatal visit, generally between 6 and 14 
weeks’ gestation. If screening was not conducted at the first visit, it was completed later in 
the course of prenatal care. Urine specimens were routinely collected at the community-
based outpatient obstetrics clinics. Specimens were then transported, processed and tested at 
a single hospital-based laboratory. The laboratory used SYVA EMIT immunoassay (Siemens 
Healthineers) with a cutoff of 50 ng/mL to detect 11-nor-Δ9-THC-9-COOH, a THC 
metabolite, on a Beckman AU680 automated chemistry platform. Positive immunoassays 
underwent reflex confirmatory testing by gas chromatography-mass spectrometry (GC-MS) 
selected-ion-monitoring (SIM). Urine creatinine was also tested and the urine toxicology 
screen was deemed invalid if the urine creatinine was <20 mg/dl. In cases where urine 
toxicology screens were repeated in the same pregnancy, exposure status was based on the 
results of the first urine THC screen.
Outcomes
Preterm birth: We applied a standard definition of delivery before 37 weeks gestation to 
signify preterm birth. Gestational age at delivery was identified through infant birth records 
and were based on clinical assessment at birth.
Low birth weight and Small for gestational age birth: Birth weights were obtained 
from infant birth records and from the EHR. Low birth weight was defined as <2500g. We 
assigned weight for gestational age percentiles based on reference values derived by Oken et 
al.(19) As in our prior work, a cut-off of <10th percentile was used to classify a birth as 
small for gestational age (SGA).(20, 21)
Major structural birth defects: Major structural birth defects were identified based on 
selected ICD-10-CM diagnostic codes from infant outpatient visits or as noted on the 
problem list. The list of major structural defects was adapted from prior work by our group,
(22, 23) with codes updated from ICD-9-CM to ICD-10-CM using a crosswalk developed by 
the Centers for Disease Control and Prevention Birth Defects Branch for use in the National 
Birth Defects Prevention Network.(24) In order to reduce the likelihood of capturing 
diagnostic workups for a defect that either was not confirmed or miscoded, we required 
infants have 2 or more outpatient diagnoses or that the defect was noted in the problem list. 
A list of ICD-10 codes used to identify major structural birth defects is found in Appendix 1. 
Given the availability of head circumference measurements and the potential for prenatal 
cannabis exposures to impact neurodevelopment(10), potential cases of congenital 
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microcephaly were identified through the ICD-10 code (Q02) and then confirmed through 
review of head circumference measurements at birth and at outpatient follow-up, 
standardized based on intergrowth-21st references by gestational age at birth. Congenital 
microcephaly was defined as head circumference <3rd percentile at birth and persistent at 
outpatient follow-up, after excluding secondary causes for microcephaly.
Screen positive for developmental delay: Parent completed developmental screening 
questionnaires(25) are routinely administered as part of well-baby check-ups within our 
health system, with results stored in retrievable discrete flowsheets in the EHR. The Ages 
and Stages Questionnaire III (ASQ-3) screens early communication and motor skills, 
problem-solving and personal-social skills. The Ages and Stages: Social-Emotional 
Questionnaire (ASQ-SE) is a brief survey of important social-emotional domains in infancy 
and early childhood, including self-regulation, compliance, communication, adaptive 
behaviors, autonomy, affect and interaction with people. In this study we utilized results 
from the ASQ-3 recorded at 9 months and the ASQ-SE administered at 12 months. For the 
9-month ASQ-3, we applied standard published cut-offs by area: Communication <13.97, 
Gross motor <17.82, Fine motor <31.32, Problem solving <28.72 and Personal-social 
<18.91.(26) For the 12-month ASQ-SE, consistent with published definitions, a score of >50 
indicated an abnormal screen.(27) Reliability of these tools is strong (for the ASQ-3: 0.93 
interrater reliability; 0.92 test-retest reliability,(28) 75% sensitivity and 81% specificity;(29) 
for the ASQ-SE: 0.94 test-retest reliability, 71% sensitivity and 97% specificity at 12 
months).(27)
Covariates
We collected data on maternal sociodemographic and clinical factors associated with either 
likelihood or marijuana exposures, increased risk for adverse birth or developmental 
outcomes, or both. These were identified from the EHR and included: age, race/ethnicity, 
insurance, pre-pregnancy body mass index, use of folic acid, opioid or other drug use as 
identified on their first trimester urine toxicology screen, and smoking during pregnancy. 
Maternal comorbidities occurring prior to pregnancy including hypertension, diabetes, sickle 
cell disease, lupus and other rheumatologic disorders were also evaluated as potential risks 
for preterm and SGA births. Maternal neurologic disorders including seizures were 
evaluated as women with these disorders may be more likely to have a medical prescription 
for marijuana. Use of interpreter services was also reviewed, given the potential for parental 
proficiency in English to impact results of infant developmental screening.
Analyses
We conducted descriptive analyses of sociodemographic variables. Two potential sources of 
bias in constructing the cohort were evaluated. First we compared rates of having a positive 
THC screen in women whose pregnancies linked to a live birth versus those whose 
pregnancies did not link to a live birth. Second, we compared distributions of baseline 
characteristics by THC screening results. Frequency distributions and means with standard 
deviation were reported, and statistical significance (p<0.05) was evaluated with chi-square 
or t-test, accordingly. To evaluate the association between THC exposure and adverse birth 
and developmental outcomes, frequency of events by THC screening results were estimated, 
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and unadjusted and adjusted rate ratios (RR)s with 95% confidence intervals (CI)s were 
estimated using generalized linear models. The model used a Poisson distribution with log 
link and robust variance estimation. Covariates included in the models were smoking during 
pregnancy, age, pre-pregnancy body mass index, and race/ethnicity. In addition, for infant 
developmental outcomes, gestational age was included in the model. Given the strong 
association between smoking and birth weight, in secondary analyses, the association 
between THC exposure and SGA is stratified by maternal smoking.
In preparation for conducting this study, we prepared a power analysis. With a minimum 
sample of 4,000 mother-infant pairs, an expected 5% THC exposure during first trimester 
and 80% power, with α=.05, we would be powered to detect a RR of 2.7 for major birth 
defects or an abnormal developmental screen, based on a background prevalence rate of 2 
per 100 live births. We would be powered to detect a RR of 1.8 for preterm or SGA birth, 
both with a background rate of 8 per 100 live births.
This study was approved by the HealthPartners Institutional Review Board with a waiver of 
informed consent.
Results
Of 8,592 women with a prenatal visit at one of 15 obstetric clinics within a single health 
system during 7/1/15–3/31/17, 4,500 (52%) were linked to a live born infant. Of these, 3,435 
(76%) remained eligible, undergoing urine toxicology screening during pregnancy, having a 
singleton infant with care in the health system following birth. (Figure 1) Among pregnant 
women linked to a live birth, 94% had a THC screen completed, and 8.2% were positive. A 
majority (69%) of urine THC screening was conducted between 6 and 14 weeks gestation. 
Women who did not have a THC screen recorded during pregnancy did not differ in baseline 
characteristics from those who completed the screening (data available upon request.) For 
women without linkage to a live birth, 89% had a THC screen completed and 11% were 
positive.
As compared to women with a negative THC screen in pregnancy, women with a positive 
screen were significantly younger (mean age 25.4 versus 29.9 years), more likely to be non-
Hispanic Black (39.6% versus 23.2%), have public insurance (53.0% versus 27.1%) and 
report smoking cigarettes during pregnancy (41.7% versus 5.9%). Interpreter use at one or 
more infant visits occurred for 7.7% of women with negative THC screens versus none of 
the women with positive THC screens. Other covariates, including parity, folic acid use, pre-
pregnancy body mass index, alcohol use, additional results of first trimester urine toxicology 
screens, and maternal comorbidities prior to pregnancy did not differ significantly between 
women with positive and negative urine THC screens. (Table 1)
Preterm birth, before 37 weeks gestation, occurred in 169 (5.4%) women with a negative 
THC screen versus 20 (7.1%) women with a positive THC screen. In adjusted analyses, 
these differences were not significant, with an adjusted RR (aRR) of 1.06 (95% CI: 0.64–
1.77). An SGA birth, <10th percentile, occurred in 290 (9.4%) infants born to women with a 
negative THC screen versus 53 (19.0%) infants born to women with a positive THC screen. 
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In analyses adjusting for maternal race/ethnicity, pre-pregnancy body mass index, age and 
smoking during pregnancy, having a positive urine THC screen was significantly associated 
with having an SGA birth, with an aRR of 1.69 (95% CI: 1.22–2.34). In secondary analyses 
of SGA and THC exposure, stratified by maternal smoking, the aRR was 1.42 (95% CI: 
0.93–2.15) in women who did not smoke cigarettes and 2.38 (95% CI: 1.35–4.19) in women 
who reported smoking cigarettes during pregnancy. Major structural birth defects, including 
microcephaly, were rare in both groups and were not significantly associated with in utero 
THC exposures, aRR of 0.58 (95% CI: 0.17–2.00). (Table 2)
Of the full cohort with birth outcome data, 68.7% with a negative THC screen and 54.1% 
with a positive THC screen had 9-month ASQ-3 developmental screens completed. For the 
12-month ASQ-SE developmental screens, retention rates were 57.7% among those with a 
negative THC screen and 46.6% among those with a positive THC screen. (Figure 1) In 
unadjusted and adjusted analyses, scoring below published thresholds on the ASQ-3 9-
month screen was not associated with THC exposure. For the 12-month ASQ-SE screen, 
abnormal or above the published screening threshold was noted in 9.1% of infants born to a 
mother with a positive THC screen versus 3.6% of those born to a mother with a negative 
THC screen. After adjusting for race/ethnicity, age, and smoking during pregnancy, these 
differences were not statistically significant, aRR 1.90 (95% CI: 0.92–3.91). (Table 2)
Discussion
The American College of Obstetrics and Gynecology (ACOG) encourages women who are 
pregnant or contemplating pregnancy to discontinue use of cannabis.(30) Findings from our 
observational study of over 3,000 women, including 283 with a positive THC screen in 
pregnancy, support these recommendations. We observed that cannabis exposure in 
pregnancy was relatively common and associated with a 70% increased risk of SGA birth. In 
addition, we observed a trend towards increased risk for abnormal developmental screening 
at 12 months of age among infants with in utero cannabis exposures, although the findings 
were not statistically significant in adjusted analyses.
One challenge in interpreting observational studies of cannabis exposures during pregnancy 
is how to address potential confounders or factors that may differ between cannabis users 
and non-users. In our study, 42% of women with positive urine THC screens also self-
reported smoking cigarettes during pregnancy. In contrast, less than 6% of women with 
negative THC screens smoked cigarettes. In analyses stratified by smoking status, the effect 
of THC on SGA birth was highest in women who also reported cigarette use. Other factors 
that differed significantly at baseline and could also be associated with SGA birth included 
maternal age and maternal race/ethnicity.
Overall, prior studies on the associations between maternal cannabis use and birth outcomes 
have applied varied exposure definitions, and have produced conflicting results. One recent 
systematic review and meta-analysis published in 2016, reported that maternal cannabis use 
was associated with decreased birth weight and increased risk for admission to a neonatal 
intensive care unit.(31) However, a second systematic review and meta-analysis, published 
in the same year, reported that after adjusting for tobacco exposures, cannabis use in 
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pregnancy was not associated with increased risk for preterm birth or low birth weight.(13) 
In a combined analysis of data from three longitudinal cohorts, cannabis use alone was 
associated with lower birth weight and co-use of cannabis and tobacco was not associated 
with additional risks.(32) Two recent large population-based studies from Canada have 
found prenatal cannabis exposures were associated with preterm and SGA birth.(33, 34) In 
contrast, in the current study we found maternal cannabis exposure was positively associated 
with SGA birth, but not associated with low birth weight or preterm birth.
Prior studies of cannabis use in pregnancy and developmental outcomes in children have 
more consistently demonstrated harm. In a study of 648 children, maternal self-report of 
heavy cannabis use in first trimester was associated with lower verbal reasoning scores and 
heavy use in second trimester was associated with deficits in short-term memory.(35) By age 
10, prenatal cannabis exposures have been associated with increased hyperactivity, 
impulsivity and inattention by parent report and increased teacher reported delinquency.(36) 
We observed a trend towards a positive association between cannabis exposure early in 
pregnancy and having an abnormal ASQ-SE at 12 months of age, although results were not 
significant in adjusted analyses. Our cohort retention at 12 months of age was approximately 
57%, with increased loss to follow-up among mothers with positive THC screens in 
pregnancy. With a background rate of abnormal 12-month ASQ-SE screening of 3 to 4%, we 
were underpowered to detect even a 2-fold increase associated with maternal cannabis use. 
As the validity of the ASQ-SE to detect true social-emotional difficulty increases with the 
child’s age at screening(27)continued monitoring of development with a larger cohort and 
over a longer follow-up period is needed.
The findings we report should also be considered in the context of limitations in our 
measurement tools. The ASQ-3 and ASQ-SE are commonly used in pediatric primary care 
practice for identifying infants and young children at risk for developmental delays and 
socioemotional difficulties. However, these are parent-report surveys and not diagnostic 
tools. The ASQ-3 and ASQ-SE have been used in prior studies of neurodevelopment 
following prenatal exposures.(37, 38) Nevertheless, at this early age these developmental 
screens may not be optimally sensitive to the types of cognitive and self-regulatory 
difficulties detected through formal neurocognitive assessments later in childhood following 
in utero cannabis exposures. Future investigations should include formal neurocognitive 
assessments, including measurement of emerging executive function skills, to fully evaluate 
potential detrimental effects of prenatal cannabis exposures as described in prior studies.(11)
A number of mechanisms have been proposed as potential pathways for THC to impact 
embryologic and fetal development, including through the reduction of folic acid, inhibition 
of vascular endothelial growth factor, induction of apoptosis, and inhibition of cell 
migration.(39) THC is stored in fat deposits in maternal and fetal tissue. The typical half-life 
for THC is 8 days; frequent users may have THC detected in blood or urine up to 30 days 
after last use. Although the majority of urine toxicology screening was conducted between 6 
and 14 weeks gestation, there was heterogeneity in the timing of screening, limiting our 
ability to identify risks by timing of cannabis exposure in pregnancy. Furthermore, given the 
sample size, we were not able to compare women with a single positive screen versus those 
with continued cannabis use during pregnancy. In addition, we were not able to assess the 
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cannabis exposure dose or route. The risks associated with cannabis exposure may be 
increased when cannabis is smoked as compared to ingested, as combustion releases 
numerous potentially harmful toxins and carcinogens.(40)
Our study was also underpowered to detect associations between individual major structural 
birth defects and maternal cannabis use, as background prevalence rates for individual 
defects are in the range of 1–10 per 10,000 births. As such, we applied a composite outcome 
of any pre-specified major structural defect and found no association with prenatal cannabis 
exposure. Also, there was potential for misclassification of exposure status. Women with an 
initial negative urine THC screen are generally not screened again later in pregnancy yet 
exposures may occur, potentially biasing results to the null. Finally, we were only able to 
capture results of developmental screening for a subset of the full cohort undergoing 
maternal urine toxicology screening and those with positive THC screens were more likely 
to be lost to follow-up at 9 and 12 months.
Despite these limitations, the current study provides timely and needed data on the 
prevalence and potential risks of maternal cannabis use during pregnancy among women 
receiving care in a community-based integrated health system. Additional studies with larger 
cohorts, longer follow-up, and more extensive neurodevelopmental screening are needed.
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Figure 1. Identification of cohort, inclusions and exclusions
THC = Tetrahydrocannabinol;
ASQ-3 = Ages and Stages Questionnaire III;
ASQ-SE = Ages and Stages Questionnaire, Social-Emotional
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Table 1.
Baseline characteristics of women by urine tetrahydrocannabinol (THC) exposure in pregnancy
THC negative n=3152 THC positive n=283
Maternal age in years * Mean (SD) 29.9 (5.0) 25.4 (5.3)
Maternal race/ethnicity* N (%)
 Non-Hispanic Asian 489 (15.5) 2 (<1)
 Non-Hispanic African American 732 (23.2) 112 (39.6)
 Hispanic 140 (4.4) 20 (7.1)
 Non-Hispanic White 1578 (50.1) 121 (42.8)
 Other or not available 213 (6.8) 28 (9.9)
Body mass index (kg/m2) Mean (SD) 27.5 (6.4) 28.1 (7.2)
Number of live births Mean (SD) 2.1 (1.3) 1.9 (1.1)
Interpreter use at infant visits* N (%) 243 (7.7) 0 (0)
Medicaid* N (%) 853 (27.1) 150 (53.0)
Folic acid use in pregnancy‡ N (%) 2861 (90.8) 265 (93.6)
Smoking during pregnancy* N (%) 186 (5.9) 118 (41.7)
Self-report alcohol prior 12 months N (%) 1008 (32.0) 93 (32.9)
Urine toxicology screen completed between 6–14 weeks gestation N (%) 2192 (70.1) 188 (66.4)
Positive opioid urine toxicology N (%) 17 (0.5) 4 (1.4)
Other positive urine toxicology‡‡ N (%) 28 (0.9) 6 (2.1)
Pre-existing comorbidities‡‡‡ N (%) 121 (3.8) 16 (5.7)
THC = Tetrahydrocannabinol;
‡
Folic acid use based on active medication list in electronic health record;
‡‡Other positive urine toxicology includes amphetamines, cocaine, phenylcyclindine, benzodiazepines, baribiturates
‡‡‡
Pre-existing maternal comorbidities include: epilepsy and other neurologic disorders, diabetes, hypertension, sickle cell disease and other 
hematologic disorders, lupus and other rheumatologic disorders. Conditions identified through problem lists and diagnoses in 6 months prior to last 
menstrual period;
*
Differences between THC positive and THC negative in pregnancy significant at p<.0001
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Table 2.
Birth and developmental screening outcomes by urine tetrahydrocannabinol (THC) exposure, with and without 
adjustment
THC negative THC positive Unadjusted Adjusted****
n n (%) n n (%) RR (95% CI) RR (95% CI)
Preterm birth <37 weeks gestation 3127 169 (5.4) 283 20 (7.1) 1.31 (0.83–2.05) 1.06 (0.64–1.77)
Low birth weight <2500g 3090 114 (3.7) 279 23 (8.2) 2.23 (1.44–3.47) 1.27 (0.86–1.86)
Small for gestational age <10th percentile 3090 290 (9.4) 279 53 (19.0) 2.02 (1.53–2.67) 1.69 (1.22–2.34)
Major structural birth defect* 3152 52 (1.6) 283 3 (1.1) 0.65 (0.20–2.06) 0.58 (0.17–2.00)
ASQ-SE 12-month Abnormal** 1819 66 (3.6) 132 12 (9.1) 2.51 (1.37–4.58) 1.90 (0.92–3.91)
ASQ-3 9-month Subscale Below Cutoff***
 Communication 2168 35 (1.6) 153 2 (1.3) 0.81 (0.20–3.33) 1.08 (0.27–4.26)
 Gross Motor 2167 86 (4.0) 153 5 (3.3) 0.82 (0.34–1.99) 0.92 (0.35–2.41)
 Fine Motor 2168 532 (24.5) 153 26 (17.0) 0.69 (0.49–0.98) 0.91 (0.63–1.31)
 Problem Solving 2166 174 (8.0) 153 12 (7.8) 0.98 (0.56–1.71) 1.39 (0.75–2.57)
 Personal-Social 2165 133 (6.1) 153 6 (3.9) 0.64 (0.29–1.41) 0.79 (0.34–1.85)
THC = Tetrahydrocannabinol; ASQ-3 = Ages and Stages Questionnaire III; ASQ-SE: Ages and Stages Questionnaire: Social-Emotional; RR = 
Rate ratio
*
Defined as having 2 or more diagnoses in first year of life or defect noted in problem list;
For full list of birth defects, please see Appendix A
**ASQ-SE 12-month abnormal defined as above 50
***ASQ-3 9-month Communication Subscale Cutoff=13.97; ASQ-3 9-month Gross Motor Subscale Cutoff=17.82; ASQ-3 9-month Fine Motor 
Subscale Cutoff=31.21; ASQ-3 9-month Problem Solving Subscale Cutoff=28.72; ASQ-3 9-month Personal-Social Subscale Cutoff=18.91;
****
Rate ratios for preterm birth, SGA birth and major structural birth defects adjusted for maternal race/ethnicity, maternal age, body mass index, 
and smoking during pregnancy; rate ratios for ASQ-3 and ASQ-SE results also adjusted for gestational age at birth.
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